Posted by Michael Wonder on 28 Jun 2020
Highlights from the June 22-25 CHMP meeting
26 June 2020 - EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its June 2020 meeting.
The Committee recommended granting a conditional marketing authorisation for Veklury (remdesivir), for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen. Remdesivir is the first medicine against COVID-19 to be recommended for authorisation in the EU.
The CHMP recommended granting a conditional marketing authorisation for Idefirix* (imlifidase), the first treatment for adult patients waiting for a kidney transplant who are highly sensitised against tissue from the donor and who have a positive crossmatch test against an available kidney from a deceased donor.
